Hostname: page-component-6898cfcb55-th4rj Total loading time: 0 Render date: 2026-11-11T05:20:09.656Z Has data issue: false hasContentIssue false
  • English
  • Français

Antibiotic prescription during the COVID-19 pandemic: a biphasic pattern – ERRATUM

Published online by Cambridge University Press:  26 August 2020

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Erratum
Information
Infection Control & Hospital Epidemiology , Volume 41 , Issue 11 , November 2020, pp. 1373
Check for updates
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

In the above mentioned article by Abelenda-Alonso et al1, the wrong figure file was used for Figure 1 in the final published version of record. The correct Figure 1 appears below. The publisher apologizes for the error.

Fig. 1.

Total antimicrobial consumption and comparative consumption of a amoxicillin/clavulanate and broad-spectrum antibiotics during the first 4 months of 2019 and 2020. Broad-spectrum antibiotics included cefepime, piperacillin/tazobactam, meropenem, imipenem, and ertapenem. Note. DDD, defined daily dose.

References

Abelenda-Alonso, G, Padullés, A, Rombauts, A, et al. Antibiotic prescription during the COVID-19 pandemic: a biphasic pattern. Infect Control Hosp Epidemiol 2020 July 30 [Epub ahead of print]. doi: 10.1017/ice.2020.381 Google Scholar
Figure 0

Fig. 1.Total antimicrobial consumption and comparative consumption of a amoxicillin/clavulanate and broad-spectrum antibiotics during the first 4 months of 2019 and 2020. Broad-spectrum antibiotics included cefepime, piperacillin/tazobactam, meropenem, imipenem, and ertapenem. Note. DDD, defined daily dose.